An FDA Panel Just Endorsed These Unproven Peptides

An FDA advisory committee voted to recommend three unapproved peptides for compounding and gave a separate favorable vote on a fourth after reviewing the evidence.

FDA scientists opposed the move, saying there is not enough evidence on safety or effectiveness, while supporters argued patients should have regulated access to products already in the gray market.

The decision could expand legal access to peptides such as BPC-157, KPV, TB-500, and MOTs-C, with implications for patient safety and pharmacy oversight.

It may also accelerate the growth of the wellness and telehealth peptide market and widen the reach of unproven treatments.